

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## 上海復旦張江生物醫藥股份有限公司

**Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code:1349)**

### **ANNOUNCEMENT OF OBTAINING CLINICAL TRIAL APPROVAL FOR HIGH BIO- ACTIVITY RECOMBINANT HUMAN TNF RECEPTOR**

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (上海復旦張江生物醫藥股份有限公司) (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of the directors (the “**Board**”) of the Company is pleased to announce that, as at the date of this announcement, the Company has obtained clinical trial approval issued by China Food and Drug Administration (“**CFDA**”) for high bio-activity recombinant human TNF receptor (Recombinant fusion protein of human tumor necrosis factor receptor mutant and Fc fragment injection). The approval No is 2014L00653. The project will enter into the clinical trial phase I.

High bio-activity recombinant Human TNF receptor is intended to be used for the treatment of self-immunological diseases, such as Arthritis. The Company holds independent intellectual property right. It is one of the key R&D projects of the Group.

High bio-activity recombinant Human TNF receptor is one of the projects cooperated with Shanghai Pharmaceuticals Holding Co., Ltd. Details are set out in the circular of the Company dated 12 April 2013.

By Order of the Board

**Wang Hai Bo**

Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Ms. Fang Jing (Non-executive Director)

Ms. Ke Ying (Non-executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Pan Fei (Independent Non-executive Director)

Mr. Cheng Lin (Independent Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

**Shanghai, the PRC**

20 May 2014

*\* For identification purpose only*